MOH
- Status: likely_approved
Omnipaque 180 (IOHEXOL) regulatory status in United Arab Emirates.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH has authorised it.
GE HealthCare is the originator. The local marketing authorisation holder may differ — check the official source linked above.